Management of recurrent hepatitis C virus after liver transplantation

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16409-16417

  Jiménez Pérez, Miguel ^a,c   González Gre, Rocío ^a   Ro Muñoz, Francisco Javier ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b NIJ SMELLINGHE HOSPITAL   (Netherlands)

^c H R Carlos Haya   (Spain)

Author keywords

Hepatitis C virus; Liver transplantation; Recurrence: Treatment

Indexed keywords

BOCEPREVIR; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON; RIBAVIRIN; STEROID; TELAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CHOLESTATIC HEPATITIS; DISEASE COURSE; GRAFT FAILURE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NONHUMAN; PROGNOSIS; RECURRENT INFECTION; REINFECTION; RETRANSPLANTATION; SURVIVAL; VIREMIA; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DRUG COMBINATION; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; LIVER NEOPLASMS; MORTALITY; RECURRENT DISEASE; RISK FACTOR; TIME; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918809514     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16409     Document Type: Article

References (78)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual data report. Available from: URL: http: //optn.transplant.hrsa.gov/data/annualreport.asp. Accessed Feb, 2014
2. Guillouche P, Féray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther 2011; 33: 163-174 [PMID: 21083593 DOI: 10.11111/J.1365-2036.2010.04505]
3. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231 [PMID: 14742986 DOI: 10.1097/01. TP.000101738.27552.9D]
4. Roche B, Samuel D. Hepatitis C virus: Up to the Minute. Liver Transpl 2010; 16 Suppl 2: S26-S35 [DOI: 10.1002/lt.22154]
5. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation, J Hepatol 2007; 46: 459-465 [PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017]
6. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287 [PMID: 18571272 DOI: 10.1016/j.jhep.2008.05.002]
7. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018]
8. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687 [PMID: 11870384 DOI: 10.1053/ jhep.202.31773]
9. Berenguer M, Rayón JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, Carrasco D, López-Andujar R, Mir J, Berenguer J. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7: 790-796 [PMID: 11552213 DOI: 10.1053/jlts.2001.23794]
10. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayón M, San Juan F, Landaverde C, Mir J, Berenguer J. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003; 9: 1152-1158 [PMID: 14586875 DOI: 10.1053/jlts.2003.50240]
11. Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothematic EAST conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45: 127-143 [PMID: 16723165 DOI: 10.1016/j.jhep.2006.05.001]
12. Carrión JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34 [PMID: 19839063 DOI: 10.1002/hep.23240]
13. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueño MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858 [PMID: 11003634 DOI: 10.1053/ jhep.2000.17924]
14. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M, Córdoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684 [PMID: 10782918 DOI: 10.1016/so168-8278(00980231-7]
15. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340 DOI: 10.1053/gast.2002.32418]
16. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071 [PMID: 19718647 DOI: 10.1002/ lt.21784]
17. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, Reed AI, Hemming AW, Liu C, Crawford JM, Nelson DR. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247 [PMID: 15376304 DOI: 10.1002/lt.20238]
18. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881 [PMID: 19938138 DOI: 10.1002/It.21954]
19. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Post-transplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670 [PMID: 19938136 DOI: 10.1002/It.21952]
20. Pérez MJ, García DM, Taybi BJ, Daga JA, Rey JM, Grande RG, Lombardo JD, López JM. Cardiovascular risk factors after liver transplantation: analysis of related factors. Transplant Proc 2011; 43: 739-741 [PMID: 21486587 DOI: 10.1016/j.transproceed.2011.03004]
21. Jiménez-Pérez M, García DM, Grande RG, Daga JA, Pulido LB, Aguilar MD, Bravo MA, López JM, de la Mata Garcia MM. Analysis of the recurrence of hepatitis C virus after liver transplantation: results of the Andalusian liver registry. Transplant Proc 2013; 45: 276-278 [PMID: 23375315 DOI: 10.1016/j.transproceed.2012.08.015]
22. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 Suppl 1: 89-96 [PMID: 17958649 DOI: 10.1111/J.1365-2893.2007.00920]
23. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-456 [PMID: 15763325 DOI: 10.1016/j.jhep.2005.01.011]
24. Perez-Daga JA, Santoyo J, Suárez MA, Fernández-Aguilar JA, Ramírez C, Rodríguez-Cañete A, Aranda JM, SánchezPérez B, Montiel C, Palomo D, Ruiz M, Mate A. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. Transplant Proc 2006; 38: 2468-2470 [PMID: 17097969 DOI: 10.1016/j.transproceed.2006.08.077]
25. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, Rosser BG, Satyanarayana R, Grewal HP, Hewitt WR, Harnois DM, Crook JE, Steers JL, Dickson RC. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84-92 [PMID: 14724440 DOI: 10.1097/01.TP.0000095896.07048.BB]
26. Pine JK, Aldouri A, Young AL, Davies MH, Attia M, Toogood GJ, Pollard SG, Lodge JP, Prasad KR. Liver transplantation following donation after cardiac death: an analysis using matched pairs. Liver Transpl 2009; 15: 1072-1082 [PMID: 19718634 DOI: 10.1002/It.21853]
27. Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant 2005; 5: 399-405 [PMID: 15644001 DOI: 10.1111 /j.1600-614.2004.00704]
28. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324 [PMID: 21254179 DOI: 10.1002/ hep.24074]
29. Brocato M, Trotter JF, Forman L, Riccardi S, Burton JR, Everson GT, Smith M, Susskind BM, Spritz R, Kam I, Klintmalm G. Genetion variation of IL-28B associated with severity of HCV recurrence following liver transplantation. AASLD 2010. Abstract poster 1158. Hepatology 2010; 52 suppl 4: 875A [DOI: 10.1002/hep.23993]
30. Hanouneh I A, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293 [PMID: 18756451 DOI: 10.1002/It.21312]
31. González-Grande R, Jiménez-Perez M, Sáez-Goméz AB, Rodrigo-López JM. Metabolic syndrome after liver transplantation. In: Abdeldayem H, Allam N, editors. Liver transplantation-Technical issues and complications. Rijeka (Croatia): InTech, 2012: 349-360
32. McCaughan GW. Immunosuppression for HCV following liver transplantation: enough is just enough. Transplantation 2004; 78: 1413-1414 [PMID: 15599303 DOI: 10.1097/01. TP.0000140976.61265.61]
33. Samonakis DN, Triantos CK, Thalheimer U, Quaglia A, Leandro G, Teixeira R, Papatheodoridis GV, Sabin CA, Rolando N, Davies S, Dhillon AP, Griffiths P, Emery V, Patch DW, Davidson BR, Rolles K, Burroughs AK. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386-395 [PMID: 15776454 DOI: 10.1002/It.20344]
34. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722 [PMID: 16487616 DOI: 10.1016/j.jhep.2006.01.005]
35. Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, Lang H, Karaliotas C. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22: 892-905 [PMID: 19453997 DOI: 10.1111 /j.1432-2277.2009.00893]
36. Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, Montgomery RA, Cameron AM, Maley WR. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-525 [PMID: 18383081 DOI: 10.1002/lt.21396]
37. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-29 [PMID: 17192906 DOI: 10.1002/lt.21035]
38. Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl 2006; 12:1464-1472 [PMID: 17004259 DOI: 10.1002/lt .20802]
39. O'Grady JG, Hardy P, Burroughs AK, Elbourne D. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137-141 [PMID: 17109723]
40. Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805-812 [PMID: 21963086 DOI: 10.1016/j.clinre.2011.04.009]
41. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios G, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355 [PMID: 16869810 DOI: 10.1111 /j.1600-6143.2006.01470]
42. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687 [PMID: 18294165 DOI: 10.1111/ j.1600-6143.2007.02126.x]
43. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, Merli M, Strazzabosco M, Tisone G. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis G. J Hepatol 2007; 46: 1009-1017 [PMID: 17328985 DOI: 10.1016/ j.jhep.2006.12.017]
44. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262 [PMID: 16025497 DOI: 10.1002/hep.20793]
45. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355 [PMID: 11965579 DOI: 10.1053/jlts.2002.31748]
46. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JY, Mor E, Bodian G, Guy SR, Schwartz ME, Emre S, Bodenheimer HC, Miller CM. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-838 [PMID: 9731580 DOI: 10.1002/hep.510280334]
47. Chalasani N, Manzarbeitia G, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298 [PMID: 15660392 DOI: 10.1002/ hep.20560]
48. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Koku do N. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-1311 [PMID: 15548968 DOI: 10.1097/01. TP.0000142677.12473.E5]
49. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124 [PMID: 15636619 DOI: 10.1111/j.1600-6143.2004.00648-x]
50. Carrión JA, Navasa M, García-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756 [PMID: 17484872 DOI: 10.1053/ j.gastro.2007.03.041]
51. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010; (1): CD006803 [PMID: 20091608 DOI: 10.1002/14651858]
52. Aytaman A, Kaufman M, Terrault NA. Management of posttransplant hepatitis C infection. Curr Opin Organ Transplant 2010; 15: 301-309 [PMID: 20445452 DOI: 10.1097/ MOT.0b013e3283398237]
53. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayón JM, Berenguer J. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-1076 [PMID: 16622844 DOI: 10.1002/ lt.20737]
54. Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. Transplant Proc 2010; 42: 666-668 [PMID: 20304219 DOI: 10.1016/j.transproce ed.2010.2.008]
55. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shir abe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-185, 1577-185, [PMID: 20708617 DOI: 10.1053/ j.gastro.2010.07.058]
56. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, Martorell J, Navasa M, Forns X. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057 [PMID: 21466653 DOI: 10.1111/j.1600-6143.2011.03491.x]
57. Feliu A, Carrión JA, Massaguer A, Martinez-Bauer E, García-Retortillo M, González P, Costa J, Sánchez-Tapias JM, Forns X. Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. J Viral Hepat 2006; 13: 544-551 [PMID: 16901285 DOI: 10.HH/j.1365-2893.2006.00714.x]
58. Firpi RJ, Soldevila-Pico G, Morelli GG, Cabrera R, Levy C, Clark VC, Suman A, Michaels A, Chen C, Nelson DR. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci 2010; 55:196-203 [PMID: 19798576 DOI: 10.1007/ s10620-009-0981-3]
59. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538 [PMID: 21506241 DOI: 10.1002/lt.22271]
60. Walter T, Scoazec JY, Guillaud O, Hervieu V, Chevallier P, Boillot O, Dumortier J. Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact. Liver Transpl 2009; 15: 54-63 [PMID: 19109834 DOI: 10.1002/ lt.21652]
61. Carrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962-970 [PMID: 20800307 DOI: 10.1016/ j.jhep.2010.06.006]
62. Marti J, Charco R, Ferrer J, Calatayud D, Rimola A, Navasa M, Fondevila C, Fuster J, García-Valdecasas JC. Optimization of liver grafts in liver retransplantation: a European single-center experience. Surgery 2008; 144: 762-769 [PMID: 19081018 DOI: 10.1016/j.surg2008.06.029]
63. Markmann JF, Gornbein J, Markowitz JS, Levy MF, Klintmalm GB, Yersiz H, Morrisey M, Drazan K, Farmer DG, Ghobrial RM, Goss J, Seu P, Martin P, Goldstein LI, Busuttil RW. A simple model to estimate survival after retransplantation of the liver. Transplantation 1999; 67: 422-430 [PMID: 10030290 DOI: 10.1097/00007890-199902150-00015]
64. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29: 365-370 [PMID: 9918911 DOI: 10.1002/hep.510290221]
65. Kwo PY, Lawitz E, McCone J, Schiff ER, Vierling J, Pound D, Davis M, Galati J, Gordon S, Ravendhran N, Rossaro L, Anderson F, Jacobson I. Response- guided therapy for boceprevir combination treatment; results from HCV SPRINT-1. Hepatology 2009; 50 Suppl 4:1035A [DOI: 10.1002/hep.23306]
66. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650]
67. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
68. Product information. Victrelis (boceprevir). Whitehouse Station: NMC, Inc; 2011. Available from: URL: http://www. accessdata.fda.gov/drugsatfda-docs. Accessed Feb, 2014
69. Product information. Incivek (telaprevir). Cambridge, MA:Vertex Pharmaceuticals Incorporated; 2011. Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs. Accessed Feb, 2014
70. Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S, Larrey D, Cacoub P, de Ledinghen V, Bourlière M, Bronowicki JP. Safety of Telaprevir or Boceprevir in Combination with Peginterferon alfa/Ribavirin, in Cirrhotic Non Responders. First Results of the French Early Access Program (ANRS CO20-CUPIC). J Hepatol 2012; 56 Suppl 2: S4 [DOI: 10.1016/50168-8278(12)60022-1]
71. Hsu SH, Yeh ML, Wang SN. New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol 2013; 2013: 890517 [PMID: 23710205 DOI: 10.1155/2013/890517]
72. Hulskorte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630 [PMID: 22576324 DOI: 10.1002/ hep.25831]
73. Coilly A, Roche B, Botta-Fridlun D, Leroy V, Pageaux PG, Si-Ahmed SN, Antonini TM, Samuel D, Duclos-Vallee JC. Efficacy ad safety of protease inhibitors for several hepatitis C recurrence after liver transplantation: a first multicenter experience, J Hepatol 2012; 56 suppl 2: S21 [DOI: 10.1016/ SOI68-8278(12)60061-0]
74. Kwo P, Ghabril M, Lacer da M, Vinayek R, Tector AJ, Fridell J, Vianna R. Use of telaprevir plus peginterferon(ribavirin for null responders postOL with advanced fibrosis/ cholestatic hepatitis C. J Hepatol 2012; 56 Suppl 2: S86
75. Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability. Am J Transplant 2012; 12 Suppl 3:188 [DOI: 10.1111/j.1600-6143.2012.04112.x]
76. Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, I de K, Tashiro H, Ohdan H, Chayama K. Two patients treated with pegylated interferon/ ribavirin/ telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2014; 44: 1259-1264 [PMID: 24382214 DOI: 10.1111/hepr.12296]
77. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One 2013; 8: e80528 [PMID: 24265827 DOI: 10.1371 /journal.pone.0080528]
78. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700 [PMID: 23696372 DOI: 10.1002/It.23669]